GPCR Stock — Structure Therapeutics Inc.: Cash, EV, Pipeline

Share price

$37.13

Market cap

$2,647.7M

Cash

$1,342.7M

Enterprise value

$1,305.0M

Balance sheet

Cash	$1,342.7M
Debt	$0.0M
Net cash	$1,342.7M
Enterprise value	$1,305.0M
Basic shares	213.7M shares
Fully diluted shares	243.7M shares
Fully diluted market cap	$9,047.0M
Cash per share	$6.28

Cash figures as of 2026-06-30. Database snapshot: 2026-09-22.

Price history

Loading GPCR daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Oct 13 - Nov 24	Aleniglipron	Phase 2	Obese; Obesity; Obesity Type 2 Diabetes Mellitus	—
Apr 12 - May 24	ACCG-2671	Phase 2	Obesity	—
Oct 13 - Nov 24	Aleniglipron	Phase 3	Obesity; Overweight; Chronic Weight Management	2H 2028
Oct 13 - Nov 24	aleniglipron	Phase 3	Obesity; Overweight; Chronic Weight Management	2H 2028

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

aleniglipron

Phase 3 · Active Modality: small molecule (oral, once-daily)

Aliases GSBR-1290

Target GLP-1R

Partnerships Schrodinger (co-founder and strategic discovery partner); Genentech/Roche (December 2025 non-exclusive license to a different class of oral GLP-1R agonist patents; $100M upfront)

Indications

Obesity, overweight and related conditions (Phase 3)

Catalysts

— third quarter of 2026
— second half of 2026
— second half of 2026
— second half of 2026

Status note Most advanced candidate; Phase 3 ACCOMPLISH program (two trials) initiated August 2026 following end-of-Phase-2 correspondence with FDA.

ACCG-2671

Phase 1 · Active Modality: small molecule (oral)

Target amylin receptor

Partnerships Schrodinger (discovery collaboration)

Indications

Obesity (Phase 1)

Catalysts

— third quarter of 2026

Status note Lead oral amylin receptor agonist candidate; Phase 1 initiated December 2025.

ACCG-3535

Preclinical · Active Modality: small molecule (oral)

Target amylin receptor

Partnerships Schrodinger (discovery collaboration)

Indications

Obesity (Preclinical)

Catalysts

— fourth quarter of 2026

Status note Second oral amylin development candidate, selected November 2025.

LTSE-2578

Phase 1 · Active Modality: small molecule (oral)

Target LPA1R

Partnerships Schrodinger (discovery collaboration via Lhotse Bio)

Indications

Idiopathic pulmonary fibrosis (IPF) (Phase 1)

Status note Phase 1 single- and multiple-ascending-dose trial completed July 2025; company is considering strategic alternatives for the Phase 2-ready program in non-metabolic indications.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Aleniglipron
Lead indication	Obesity
Lead phase	Phase 3
Active trials	5
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07654361	Phase 3	Recruiting	Sponsor	GPCR	—	Obesity; Overweight; Chronic Weight Management	2H 2028
NCT07654374	Phase 3	Recruiting	Sponsor	GPCR	—	Obesity; Overweight; Chronic Weight Management	2H 2028
NCT07815678	Phase 2	Recruiting	Sponsor	GPCR	—	Obesity	—
NCT07169942	Phase 2	Active, not recruiting	Sponsor	GPCR	—	Obesity, Overweight, or Chronic Weight Management	—
NCT07400588	Phase 2	Active, not recruiting	Sponsor	GPCR	—	Obese; Obesity; Obesity Type 2 Diabetes Mellitus	—
NCT04558450	Not disclosed	Recruiting	Collaborator	Assistance Publique - Hôpitaux de Paris	—	Covid19; Arterial Stiffness; Endothelial Dysfunction	—

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 6 active trials for Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	2,209,400	+733,997	2.25%	2026-08-14
RTW Investments	1,607,507	+1,607,507	0.74%	2026-08-14
Baker Bros. Advisors	1,432,529	no change	0.39%	2026-08-14
Logos Global Management	500,000	no change	1.16%	2026-08-14
Sphera Biotech	28,600	-22,200	0.22%	2026-08-14
ADAR1 Capital Management	17,500	+17,500	0.04%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

GPCR — Structure Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders